Press Release Oct 01 2025
Filed with NSE · · 3 pages · English
Summary by 6ix AI
The U.S. Food and Drug Administration has issued a Complete Response Letter that Sentynl and Zydus must address to clarify the path forward for the drug's approval. The press release emphasizes Zydus's commitment to working with the FDA to resolve the issues raised and to pursue resubmission of the NDA promptly.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Sep 23 2025
- Press Release Sep 21 2025
- Press Release Sep 15 2025
- Press Release Sep 05 2025
- Press Release Sep 04 2025
Later from Zydus Lifesciences
- Press Release Oct 06 2025
- Press Release Oct 24 2025
- Press Release Oct 29 2025
- Press Release Nov 04 2025
- Press Release Nov 05 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences